Natalizumab-sztn · Regulatory label update

FDA supplemental approval: Tyruko (REMS)

U.S. Food and Drug Administration · July 23, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

This is an FDA supplemental approval action dated 23 July 2026 for TYRUKO (natalizumab-sztn), a biosimilar manufactured by Sandoz. The supplement addresses REMS (Risk Evaluation and Mitigation Strategy) requirements. This record documents a regulatory decision, not clinical efficacy or safety trial results.

What was studied

Regulatory label update.

Key findings

Supplemental BLA approval granted for TYRUKO (natalizumab-sztn) on 2026-07-23 Submission class is REMS, indicating a risk mitigation strategy requirement Product formulation: 300 mg per 15 mL injection (20 mg/mL concentration)

Safety

This record does not contain clinical trial results, efficacy data, or comparative safety evidence.

Who this may help

This is a regulatory action, not a clinical evidence report. Clinicians should refer to the approved REMS requirements and prescribing information for safety monitoring and patient eligibility criteria; this record does not report clinical trial efficacy or comparative safety data.

Plain-language summary

FDA supplemental approval action for a REMS (Risk Evaluation and Mitigation Strategy) regulatory requirement; does not contain clinical trial data or efficacy evidence.

Reported figures

Quoted from the source exactly as published.

Approval date2026-07-23

BLA application numberBLA761322

Product concentration20 mg/mL

Clinical bottom line

Caveats

This record does not contain clinical trial results, efficacy data, or comparative safety evidence.
The record does not specify what REMS requirements were added, modified, or approved.
No patient population, study design, or clinical outcomes are reported.
Approval date appears to be a future date (2026), suggesting this may be a template or example record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory record; no study design applicable.

Directness

insufficient

Regulatory action record; does not report clinical outcomes.

Consistency

insufficient

Single regulatory action; consistency not assessable.

Risk of bias

insufficient

Regulatory approval; bias assessment does not apply.

Sample adequacy

insufficient

No clinical trial or patient population data reported.

Source abstract

Drugs@FDA record for application BLA761322. This is a regulatory action record, not a clinical study. Brand name: TYRUKO. Active ingredient: NATALIZUMAB-SZTN. Sponsor: SANDOZ INC. Submission type: SUPPL (supplement). Submission class: REMS. Approval status date: 2026-07-23. Products: TYRUKO, INJECTABLE, INJECTION, NATALIZUMAB-SZTN 300MG/15ML(20MG/ML).

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

SandozNatalizumab-sztn